Cost evaluation of an exercise oncology intervention: The exercise in all chemotherapy trial.
Cost evaluation of an exercise oncology intervention: The exercise in all chemotherapy trial.
复制标题
DOI：
10.1002/cnr2.1490
复制
发表时间：
2022-03
期刊：
影响因子：
--
通讯作者：
Schmitz KH
中科院分区：
文献类型：
--
作者：
Potiaumpai M;Doerksen SE;Chinchilli VM;Wu H;Wang L;Lintz R;Schmitz KH
有强有力的证据支持运动肿瘤学计划在积极治疗期间改善身体和心理社会结果的功效。然而，关于运动对医疗保健利用的影响以及运动肿瘤学项目的成本分析的证据很少。我们的目标是评估积极化疗期间实用的肿瘤运动运动计划 (ENACT) 对医疗保健利用率和相关成本的影响。我们对 160 名 ENACT 参与者和 75 名在癌症部位、分期、年龄范围和性别上匹配的对照参与者进行了事后分析。我们获得了每位患者参与 ENACT 时的完整医疗保健利用历史（具体针对急诊科 [ED] 就诊和入院）。对晚期乳腺癌、胃肠道癌和胰腺癌患者进行了亚组分析。即使考虑了干预成本，参与 ENACT 运动肿瘤学干预的患者的医疗费用在数字上也低于对照组的医疗费用。然而，差异没有统计学意义。我们的研究结果表明，积极化疗期间的运动肿瘤学计划对于所有癌症患者（包括晚期癌症）至少是中性的。需要进行更多研究来评估运动肿瘤学计划减少医疗保健利用率的潜力，特别是对于晚期癌症患者。
There is strong evidence supporting the efficacy of exercise oncology programs to improve physical and psychosocial outcomes during active treatment. However, there is a paucity of evidence on the effect of exercise on healthcare utilization and cost analyzes of exercise oncology programs. Our objective was to assess the effects of a pragmatic exercise oncology program (ENACT) during active chemotherapy treatment on healthcare utilization and associated costs. We conducted post‐hoc analyzes on 160 ENACT participants and 75 comparison participants matched on cancer site, stage, age range, and gender. We obtained complete healthcare utilization histories for each patient (specific to emergency department [ED] visits and hospital admissions) coinciding with their participation in ENACT. A sub‐analysis was conducted for advanced stage breast, gastrointestinal, and pancreatic cancer patients. Healthcare costs for patients who participated in the ENACT exercise oncology intervention were numerically lower than healthcare costs for the comparison group, even after accounting for the cost of the intervention. However, the differences were not statistically significant. Our findings suggest that an exercise oncology program during active chemotherapy treatment are at least cost neutral for all cancer patients, including advanced stage cancers. Additional research is warranted to evaluate the potential for exercise oncology programs to reduce healthcare utilization, particularly in advanced cancer patients.